Find your care

At UCLA Health, you receive world-class care from a team of experts in pulmonary vascular disease. Call 310-825-0527 to connect with a specialist.

A researcher using a microscope to analyze a sample

Research Program – Pulmonary Vascular Disease

The UCLA Pulmonary Vascular Disease research program is a collaborative effort among patients, providers and scientists. The program has several types of pulmonary vascular disease research:

  • Basic research — Experimental work carried out in a laboratory helps the center to better understand the fundamental cellular mechanisms of pulmonary vascular disease.
  • Clinical Research — Clinical research includes both observational studies and clinical trials that use the knowledge gained in basic research to study the benefits of new drugs.
  • Database/registry — The UCLA Pulmonary Vascular Disease registry has an ongoing longitudinal research database and biorepository study. This database is a rich source of data and biologic specimens for investigators.

Patients may be asked if they are interested in participating in a research study. Participation is voluntary. The choice of whether or not to participate in a research study will not impact patient care in any way. Research funding comes from a variety of public and private sources.

Give to the Pulmonary Vascular Disease Program >

To become involved in a research study 

Speak with the physicians in the UCLA Pulmonary Vascular Disease Program about potential research studies.
For additional information, contact the research team for the Pulmonary Vascular Disease Research Program >

Lloyd Liang
Clinical Research Project Manager

Harold Te
Clinical Research Coordinator

Lynne Yoder, RN
Clinical Research Nurse


Basic Research

We seek to better understand the molecular and cellular mechanisms of pulmonary arterial hypertension to find more effective therapies and ultimately a cure for patients. To further this goal, we employ a multifaceted and translational research strategy that combines experimental investigations using clinical specimens from patients enrolled in our studies, preclinical models of pulmonary arterial hypertension utilizing in vitro and in vivo techniques, and systems biology approaches leveraging cutting-edge sequencing technologies and multidimensional omics. 

Investigators:

Mansoureh Eghbali, PhD

Mansoureh Eghbali, PhD

Professor of Anesthesiology and Perioperative Medicine
Director, Physician Scientist Training Program
Director, Basic Science Training Environment

Jason Hong, MD, PhD

Jason Hong, MD, PhD

Health Sciences Clinical Instructor

Provider female default

Airie Kim, MD, PhD

Health Sciences Assistant Clinical Professor

Provider male default

Gregoire Ruffenach, PhD

Postdoctoral Fellow

Soban Umar, MD, PhD

Soban Umar, MD, PhD

Assistant Professor of Anesthesiology and Perioperative Medicine
Residency Research Coordinator, Anesthesiology Residency Program

Provider female default

Xia Yang, PhD

Associate Professor of Integrative Biology & Physiology

Back to top


Clinical Research

Studies Currently Enrolling:

BRAD: A Study to Evaluate Patients with Confirmed or Suspected Pulmonary Hypertension Due to Connective Tissue Disease, Liver Disease, Pulmonary Fibrosis, Unknown Causes, and Others

Principal Investigator: Rajan Saggar, MD

Sponsor: Investigator Initiated

Site: David Geffen School of Medicine at UCLA, Westwood Campus
Description: Registry and biorepository for patients with pulmonary hypertension at UCLA. The purpose of the research is to further our understanding of patients with pulmonary hypertension of any etiology, including (but not limited to) scleroderma, liver disease, rheumatoid arthritis, or unknown cause. These patients appear to have variable prognoses/survival and we are very much interested in better predicting (non-invasively) which patients may have pulmonary hypertension, since pulmonary hypertension appears to be a major cause of death in these patients.


 

Role of the Novel MicroRNA-125b in Pulmonary Hypertension Associated with Pulmonary Fibrosis

Principal Investigator: Soban Umar, MD

Sponsor: Investigator Initiated

Site: David Geffen School of Medicine at UCLA, Westwood Campus
Description: Recruiting healthy control subjects to donate blood samples for comparative analysis to patients with pulmonary hypertension


 

Pilot study to evaluate the role of endobronchial ultrasound (EBUS) in the diagnosis of acute pulmonary embolism in critically ill patients

Principal Investigator: Colleen Channick, MD

Sponsor: Investigator Initiated

Site: David Geffen School of Medicine at UCLA, Westwood Campus
Description: This is a single center, pilot study to evaluate critically ill patients diagnosed with acute pulmonary embolism using endobronchial ultrasound (EBUS). We anticipate to enroll a total of 60 subjects at Ronald Reagan UCLA Medical Center and UCLA Medical Center, Santa Monica. 20 subjects will be critically ill patients diagnosed with acute pulmonary embolism. Another 20 subjects undergoing clinical bronchoscopy as a part of their standard of care. Media including images and videos that are previously recorded for 20 patients who underwent a clinical bronchoscopy with EBUS as a part of their standard of care will also be available to our research team without consent from the patient to help supplement the data we obtain from the 20 subjects that are enrolled in the pulmonary vascular mapping substudy.


Pulmonary Embolism Response Team (PERT) Consortium Registry

Principal Investigator: Richard Channick, MD

Sponsor: PERT Consortium

Site: David Geffen School of Medicine at UCLA, Westwood Campus
Description: The PERT Registry is a multi-center Registry of patient-level data, from patients admitted to the hospital with PE for whom the PERT team has been consulted.


Neuromodulation with Percutaneous Electrical Nerve Field Stimulation for Adults with COVID-19

Principal Investigator: Nader Kamangar, MD

Sponsor: Investigator Initiated, Innovative Health Solutions (IHS)

Site: Olive View-UCLA Medical Center
Description: Randomized, double-blind, placebo-controlled study evaluating the efficacy of PENFS for the treatment of adult patients with COVID-19. Patients with confirmed infection with SARS-CoV-2 will be recruited from the inpatient medical ward after admission. New patients that require hospitalization will be identified for participation in the study.

 


A Phase I Study of the Safety and Feasibility of Central Intravenous Delivery of ALlogeneic Human Cardiosphere-Derived Stem Cells in Patients with Pulmonary Arterial Hypertension TherApy

IND #: 16686
Principal Investigator: Shelley Shapiro, MD
Sponsor: Michael I Lewis, MD, Eduardo Marbán, MD, PhD – Cedars-Sinai Heart Institute

Site: VA Greater Los Angeles Healthcare System
Description:  A Phase I study to assess the safety profile of CAP-1002 in a dose-escalation up to the maximum feasible dose (MFD), administered by central intravenous infusion in the RV outflow tract of patients with Pulmonary Arterial Hypertension, (PAH) [Idiopathic (IPAH), Heritable (HPAH), Connective Tissue Diseaseassociated, (PAH-CTD) and HIV- associated (PAH-HIV)]


An Open-label, Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder (TreT) in Subjects with Pulmonary Arterial Hypertension Currently Using Tyvaso

Protocol #: TIP-PH-101
Principal Investigator: Shelley Shapiro, MD
Sponsor: United Therapeutics Corporation

Site: VA Greater Los Angeles Healthcare System
Description:  A Phase 1b study to evaluate the safety and tolerability of Treprostinil Inhalation Powder (TreT) in subjects with pulmonary arterial hypertension (PAH) currently treated with Tyvaso®


A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Protocol #: ROR-PH-301 (APD811-301)
Principal Investigator: Shelley Shapiro, MD
Sponsor: United Therapeutics Corporation

Site: VA Greater Los Angeles Healthcare System
Description:  A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background oral therapy in subjects with World Health Organization (WHO) Group 1 pulmonary hypertension


A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous Injections of a Sustained-Release VIP Analogue, PB1046, in Adult Subjects with Symptomatic Pulmonary Arterial Hypertension

Protocol #: PB1046-PT-CL-0004
Principal Investigator: Shelley Shapiro, MD
Sponsor: PhaseBio Pharmaceuticals, Inc.

Site: VA Greater Los Angeles Healthcare System
Description:  A study to assess the safety, tolerability, and effect on pulmonary vascular resistance (PVR) of dose titrated levels of PB1046 administered subcutaneously once-weekly for 16 weeks in subjects with   symptomatic pulmonary arterial hypertension (PAH)


A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients with Pulmonary Hypertension due to Chronic Obstructive Pulmonary Disease (PH-COPD)

Protocol #: RIN-PH-304
Principal Investigator: Shelley Shapiro, MD
Sponsor: United Therapeutics Corporation and LUNG Biotechnology PBC

Site: VA Greater Los Angeles Healthcare System
Description:  A Phase 3 study to demonstrate the efficacy of inhaled treprostinil compared to placebo in improving exercise ability as measured by change from baseline in 6-Minute Walk Distance (6MWD) following 12 weeks of active treatment in subjects with PH-COPD


Studies Coming Soon:

Use of non-invasive measurement of cardiac output and stroke volume to assess risk and response to treatment in patients with pulmonary embolisms

Principal Investigator: Richard Channick, MD

Sponsor: Investigator Initiated

Site: David Geffen School of Medicine at UCLA, Westwood Campus
Description: This is a single center study to evaluate the use of non-invasive measurement of cardiac output and stroke volume to assess risk and response to treatment in patients with pulmonary embolisms. We anticipate to enroll a total of 20 subjects at Ronald Reagan UCLA Medical Center.


 

Use of non-invasive measurement of cardiac output and stroke volume to assess risk and response to treatment in patients with PAH or CTEPH

Principal Investigator: Sonia Jasuja, MD

Sponsor: Investigator Initiated, Bayer Pharmaceuticals

Site: David Geffen School of Medicine at UCLA, Westwood Campus
Description: This is a single center study to evaluate the use of non-invasive measurement of cardiac output and stroke volume to assess risk and response to treatment in patients with pulmonary arterial hypertension (PAH) and non- operable chronic thromboembolic pulmonary hypertension (CTEPH). We anticipate to enroll a total of 20 subjects at Ronald Reagan UCLA Medical Center.


An Early Feasibility Study Assessing Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System (ASPIRE PH)

Principal Investigator: Richard Channick, MD

Sponsor: Aria CV, Inc.

Site: David Geffen School of Medicine at UCLA, Westwood Campus
Description: This study is a prospective, non-randomized, single arm, multi-center early feasibility study (EFS). Since the objective of this study is to assess the safety and performance of the Aria CV PH System while simultaneously protecting patient safety, the study design is open-label and exploratory in nature. The study subjects will not be blinded prior to, during or following the procedure.


A StuDy eVAluatiNg the EffiCacy and Safety of RalinEpag To Improve Treatment OUTCOMES in PAH Patients (ADVANCE-outcomes)

 

Protocol #: ROR-PH-301 (APD811-301)
Principal Investigator: Rajan Saggar, MD
Sponsor: United Therapeutics Corporation

Site: David Geffen School of Medicine at UCLA, Westwood Campus
Description: A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.


A Study Evaluating the Long-term Efficacy and Safety of Ralinepag in subjects with PAH via an Open-label Extension (ADVANCE-EXTENSION)

Protocol #: ROR-PH-303 (APD811-303)
Principal Investigator: Rajan Saggar, MD
Sponsor: United Therapeutics Corporation

Site: David Geffen School of Medicine at UCLA, Westwood Campus
Description: A Phase 3 open-label extension (OLE) study to evaluate the long-term safety and efficacy of ralinepag in subjects with World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH).


A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous Injections of a Sustained-Release VIP Analogue, PB1046, in Adult Subjects with Symptomatic Pulmonary Arterial Hypertension

Protocol #: PB1046-PT-CL-0004
Principal Investigator: Rajan Saggar, MD
Sponsor: PhaseBio Pharmaceuticals, Inc.

Site: David Geffen School of Medicine at UCLA, Westwood Campus
Description:  A study to assess the safety, tolerability, and effect on pulmonary vascular resistance (PVR) of dose titrated levels of PB1046 administered subcutaneously once-weekly for 16 weeks in subjects with   symptomatic pulmonary arterial hypertension (PAH)


A Long-term, Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous Injections of a Sustained-Release VIP Analogue, PB1046, in Adult Subjects with Symptomatic Pulmonary Arterial Hypertension

Protocol #: PB1046-PT-CL-0006
Principal Investigator: Rajan Saggar, MD
Sponsor: PhaseBio Pharmaceuticals, Inc.

Site: David Geffen School of Medicine at UCLA, Westwood Campus
Description:  A long-term, open-label extension study of PB1046 subcutaneous injections in pulmonary hypertension subjects following completion of study PB1046-PT-CL-0004.


 

A Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the safety and efficacy of Pulsed, Inhaled, Nitric Oxide (iNO) in subjects with pulmonary hypertension associated with pulmonary fibrosis on long term oxygen therapy (Part 1 and Part 2)

Protocol #: PULSE-PHPF-001 
Principal Investigator: Rajan Saggar, MD
Sponsor: Bellerophon Pulse Technologies

Site: David Geffen School of Medicine at UCLA, Westwood Campus
Description: A double-blind, placebo-controlled study to evaluate the efficacy and optimal dose of iNO as determined by change in 6MWD (6 minute walk distance) in subjects with pulmonary hypertension associated with pulmonary fibrosis (PH-PF) currently receiving treatment with LTOT.


Active Studies No Longer Enrolling:

TRITON: The efficacy and safety of initial triple versus initial dual oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension: A multi-center, double-blind, placebo-controlled, Phase 3b study

Protocol #: AC-065A308
Principal Investigator: Rajan Saggar, MD
Sponsor: ACTELION

Site: David Geffen School of Medicine at UCLA, Westwood Campus
Description: This is a prospective, multi-center, double-blind, randomized, placebo-controlled, parallel group, Phase 3b, efficacy and safety study comparing a triple oral regimen (macitentan, tadalafil, selexipag) with a dual oral regimen (macitentan, tadalafil, placebo) in newly diagnosed, treatment-naïve subjects with PAH.


 

CATALYST:  A study of the efficacy and safety of bardoxolone methyl in patients with connective tissue disease-associated pulmonary arterial hypertension

Protocol #: 402-C-1504 RTA 402 (BARD)
Principal Investigator: Rajan Saggar, MD
Sponsor: REATA Pharmaceuticals Inc.

Site: David Geffen School of Medicine at UCLA, Westwood Campus
Description: A double-blind, randomized, placebo-controlled trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with WHO Group I CTD-PAH.


A Multicenter, Randomized, Double-blind, Placebo-controlled study to evaluate the safety and Efficacy of Oral Treprostinil in Subjects with Pulmonary Hypertension (PH) in Heart Failure with Preserved Ejection Fraction (HFpEF)

Protocol #: TDE-HF-301 SouthPaw
Principal Investigator: Rajan Saggar, MD
Sponsor: United Therapeutics

Site: David Geffen School of Medicine at UCLA, Westwood Campus
Description: A multicenter, randomized, double-blind, placebo-controlled study in subjects with WHO Group 2 PH associated with HFpEF assesses the effect of oral treprostinil compared with placebo on change in exercise capacity as measured by change in 6-Minute Walk Distance (6MWD) from Baseline to Week 24 in subjects with PH associated with HFpEF.


An open label, Extension Study of Oral Treprostinil in Subjects with Pulmonary Hypertension (PH) Associated with Heart Failure with Preserved Ejection Fraction (HFpEF) – A Long Term Follow-up to Study

Protocol #: TDE-HF-302 SouthPaw extension
Principal Investigator: Rajan Saggar, MD
Sponsor: United Therapeutics

Site: David Geffen School of Medicine at UCLA, Westwood Campus
Description: A multi-center, open-label study for eligible patients who completed Study TDE-HF-301 with the primary objective to evaluate the long-term safety of oral treprostinil in subjects with PH associated with HFpEF for subjects who completed Study TDE-HF-301.


Back to top